Are looking for Dishman Carbogen Amcis Ltd share price target, forecast, and perdition for 2024, 2025 till 2030 then you are in the right place. In this article, I will provide a detailed analysis of DCAL based on fundamentals and technical analysis. The details are given below.
Company Profile.
| Company Name | Dishman carbogen Amcis Limited |
| Sector | Pharmaceuticals & Drugs |
| Chairman | Mr. Janmejay R. Vyas |
| Incorporated | 1983 |
| Sector | Pharma |
| Address | Ahmadabad, India |
| Web Site | https://imdcal.com/ |
Dishman Carbogen Amcis Limited Company was incorporated in 1983 in Naroda near Ahmadabad, Gujarat as a manufacturer of quaternary ammonium and phosphate compounds. The company has become one of the fastest-growing companies and is a leading global outsourcing partner for the pharmaceutical industry.
The company is involved in the development and process optimization of novel drug molecules in various stages of the development process. The company’s high-quality products and services have evolved from a bulk intermediates manufacturer to a global CRAMS player through a mix of organic and inorganic growth.
The company produces APIs for pharmaceutical industries, vitamin D analogs and soft gel capsules, formulation capabilities, quaternary compounds, health, and personal care solutions, encapsulation capabilities, and HiPo capabilities.
The company has 28 Dedicated R&D labs including HiPo labs and 25 multipurpose manufacturing facilities globally. The company is approved and accredited by global health agencies and authorities like FDA, MBE, Swissmedic, Ansm, KFDA, and the World Health Organisation.
Fundamentals of Dishman carbogen Amcis Ltd.
| Market cap | 2,092.27 Cr. |
| PE | 0 |
| PB | 0.5 |
| Dividend Yield | 0 |
| Book value | 264.78 |
| Cash | 86.47 Cr. |
| Debt | 526.96 Cr. |
| Sales growth | 51.15% |
| ROE | -0.68% |
| ROCE | -0.93% |
| Profit Growth | 86.53% |
Fundamental analysis of Dishman carbogen Amcis Ltd.
The company shows sales growth of 51.15% last result that indicates the company doing well.
The profit growth of the company is 86.53% which indicates the development of the company.
The company debt is 526.96 Cr. 0.12% of the Debt to equity ratio below 1. So no interest burden on the company.
The PE ratio of the company is Zero which indicates the company is now undervalued.
The book value of the company is 264.78 which indicates the stock has more value than its share price which is good for the investor.
Earnings per share growth were 86.53% which is Good for the company.
The does not plug its stake which is good for management.
Share Holding Pattern of Company.
Promoter holding in the company is 59.32% which is more than 50% which indicates the promoter’s trust in the company’s future growth.
FII and DII holding in the company is 7.2% and 3.86% which is still a bit bad for the company.
Public holding in the company is 29.62% which creates more liquidity in the market.
Technical analysis of Dishman carbogen Amcis Ltd.
When we select any stock from a long-term investment perspective we have to analyze the monthly chart of the stock to understand the trend of the stock so now we are taking the monthly chart of the DCAL to understand the trend of the stock.
On the monthly chart, DCAL stock is moving uptrend taking support at 80. As on 12 March 2023 Dishman Carbogen’s share price today is trading at 133.45.
The RSI on the monthly chart is 48.44 which good entry opportunity now. If the stock sustains above 151 then the first target is 181, the second target is 221, and the third target will be 263.
If the stock breaks the 121 level then the downside first support is 102, the second support is 91.50 and the third support is 79.
The major resistance for the stock is first resistance is 151, second resistance is 181 and third resistance is 221.
Read More: Aarti Drugs Share Price Target
Dishman Carbogen Amcis Ltd. Share Price Target/prediction/forecast.
| Year | Minimum | Maximum |
| 2023 | 121 | 151 |
| 2024 | 138 | 181 |
| 2025 | 164 | 221 |
| 2026 | 198 | 263 |
| 2027 | 249 | 312 |
| 2028 | 283 | 395 |
| 2029 | 367 | 521 |
| 2030 | 495 | 693 |
Dishman Carbogen Amcis Ltd. Share Price Target 2023
the share price of Dishman Carbogen target for 2023 will be a minimum of 121 and a maximum will be 151.
Dishman Carbogen Amcis Ltd. Share Price Target 2024
The DCAL share price target for 2024 will be a minimum of 138 and the maximum will be 181.
Dishman Carbogen Amcis Ltd. Share Price Target 2025
The DCAL share price target for 2025 will be a minimum of 164 and a maximum will be 221.
Dishman Carbogen Amcis Ltd. Share Price Target 2026
The DCAL share price target for 2026 will be a minimum of 198 and a maximum will be 263.
Dishman Carbogen Amcis Ltd. Share Price Target 2027
The DCAL share price target for 2027 will be a minimum of 249 and a maximum will be 312.
Dishman Carbogen Amcis Ltd. Share Price Target 2028
The DCAL share price target for 2028 will be a minimum of 283 and a maximum will be 398.
Dishman Carbogen Amcis Ltd. Share Price Target 2029
The DCAL share price target for 2029 will be a minimum of 367 and a maximum will be 521.
Dishman Carbogen Amcis Ltd. Share Price Target 2030
The DCAL share price target for 2030 will be a minimum of 495 and a maximum will be 693.
Conclusion:
As of now the world is going health conscious and the government also promoting health programs so investing in the healthcare sector is good for long-term invest view. The company growth is strong. The fundamentals are good and technical the company is in a strong uptrend. So before investment check the global market conditions and sector performance. If you like this article rate this article and share it with your friends and family.
